CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Tumor-infiltrating lymphocytes provides recent survival information for early-stage HER2-low-positive breast cancer: a large cohort retrospective study.
Tumor-infiltrating lymphocytes provides recent survival information for early-stage HER2-low-positive breast cancer: a large cohort retrospective study.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
在早期 BC 中,HER2 阳性、HER2 低表达阳性和 HER2-0 队列之间未发现显著的生存差异。
回顾性纳入2017至2018年在单中心治疗的1,763名BC患者。TIL作为连续变量进行分析,并划分为低TIL(≤10%)和高TIL(>10%)用于统计分析。采用单变量和多变量Cox比例风险模型,在校正临床病理特征后检验TIL与无病生存期(DFS)的关联。
高TIL水平(>10%)与肿瘤大小(>2厘米,P=0.042)、诊断年龄(P=0.005)、Ki-67指数(>25%;P<0.001)、激素受体(HR)状态(阳性,P<0.001)、较晚病理分期(P=0.043)、亚型(P<0.001)及HER2状态(P<0.001)相关。Kaplan-Meier分析显示,HER2阳性、HER2低表达阳性和HER2-0 BC之间的DFS无显著差异(P=0.83)。在HER2低表达阳性BC和HER2未扩增BC中,高TIL患者的DFS均显著优于低TIL患者(分别P=0.015和P=0.047)。在HER2低表达阳性BC患者中,高TIL水平(>10%)与单变量(HR=0.44,95% CI 0.22–0.87,P=0.018)及多变量(HR=0.47,95% CI 0.23–0.95,P=0.035)Cox模型中的DFS改善相关。进一步亚组分析显示,在HR阳性/HER2低表达阳性BC中,高TIL(>10%)与单变量(HR=0.41,95% CI 0.19–0.90,P=0.025)及多变量(HR=0.42,95% CI 0.19–0.93,P=0.032)模型中的DFS改善相关。HR阴性/HER2-0 BC的高TIL水平在单变量Cox模型中未达统计学显著,但在多变量模型中达到显著(HR=0.16,95% CI 0.28–0.96,P=0.045)。
早期BC中,HER2阳性、HER2低表达阳性及HER2-0队列之间未见显著生存差异。高TIL水平与HER2低表达阳性患者DFS改善显著相关,尤其是HR阳性/HER2低表达亚型。
It has been reported that breast cancer (BC) with low expression of human epidermal growth factor receptor 2 (HER2) might be a distinct subtype of BC. However, the prognostic effect of low HER2 expression on BC patients remains controversial. We aim to conduct this single-institution retrospective analysis to assess HER2-low-positive BC outcomes in Chinese women and the prognostic role of TILs in HER2-low-positive early-stage BC. METHOD: We retrospectively enrolled 1,763 BC patients treated in a single institution from 2017 to 2018. TILs are regarded as continuous variables and are divided into low TILs ( 10%) and high TILs (>10%) for statistical analysis. Univariate and multivariable Cox proportional hazards regression models were used to test the associations between TILs and disease-free survival (DFS) with adjustment for clinicopathologic characteristics. RESULT: High TIL levels (>10%) were associated with tumor size (>2 cm, p = 0.042), age at diagnosis (p = 0.005), Ki-67 index (>25%; p <0.001), HR (hormone receptor) status (positive, p <0.001), advanced pathological stage (p = 0.043), subtype (p <0.001), and HER2 status (p <0.001). The Kaplan-Meier analysis indicated that no significant difference in DFS (p = 0.83) could be found between HER2-positive, HER2-low-positive, and HER2-0 BC. The DFS of HER2-low-positive BC and HER2-nonamplified BC with high levels of TILs was statistically better than that of patients with low levels of TILs (p = 0.015; p = 0.047). In HER2-low-positive BC patients with high TIL levels (>10%), DFS was significantly improved in both the univariate (HR = 0.44, 95% CI 0.22-0.87, P = 0.018) and multivariate (HR = 0.47, 95% CI 0.23-0.95, P = 0.035) Cox models. For further subgroup analysis, HR (+)/HER2-low-positive BC with high TIL (>10%) levels was associated with improved DFS in both the univariate (HR = 0.41, 95% CI 0.19-0.90, P = 0.025) and multivariate (HR = 0.42, 95% CI 0.19-0.93, P = 0.032) Cox models. The HR (-)/HER2-0 BC with high TIL (>10%) level was not statistically significant in the univariate Cox model, but it was statistically significant in the multivariate (HR = 0.16, 95% CI 0.28-0.96, P = 0.045) Cox model.
Among early-stage BC, no significant survival difference could be found between the HER2-positive, HER2-low-positive, and HER2-0 cohorts. High levels of TILs were significantly associated with improved DFS in HER2-low-positive patients, especially in the HR (+)/HER2-low-positive subtype.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。